Qingsong Health recognized as a 2026 AIGC company to watch; QSevidence named a product to watch.

On May 20, the 4th China AIGC Industry Summit, hosted by QbitAI, was held in Beijing. Qingsong Health Group (2661.HK) was invited to attend the industry event and received two honors for its continued exploration, technology innovation and real-world implementation in AI plus health.

At the summit, Qingsong Health was selected alongside technology companies including Alibaba Cloud, Baidu and 360 as a 2026 AIGC company to watch. At the same time, the group's self-developed evidence-based medical agent, QSevidence, was named a 2026 AIGC product to watch, making it one of the medical and health vertical AI products recognized by the industry.

As an important industry event focused on AIGC application and innovation, the summit brought together representatives from large models, AI agents, cloud computing, industrial applications and investment institutions. Participants discussed AIGC technology evolution, industry implementation, commercialization paths and future trends. Qingsong Health appeared as a representative medical AI company and presented its progress in bringing AI technologies into health services, medical assistance and health management through an evidence-based medical agent at the center of its product system.

During the event, Ma Xiaowu, Executive Vice President of Qingsong Health, shared the group's practice in AI plus healthcare. He noted that artificial intelligence is moving quickly from general capability building toward vertical industry application. Healthcare places higher requirements on professionalism, trustworthiness, explainability and traceability. Qingsong Health has long worked in digital health services and continues to integrate AI capabilities with real health service scenarios, aiming to contribute more through technology innovation and industry collaboration.

In recent years, Qingsong Health has continued to expand its AI plus health product and service layout, forming a digital health service system that covers health education, early disease screening, medical assistance, health management and health protection. QSevidence, the group's self-developed evidence-based medical agent, is built around evidence-based medicine methodology. It emphasizes evidence first and traceable sources, providing medical professionals with explainable, verifiable and traceable decision support, and helping medical AI evolve from a question-answering tool into an evidence-based decision assistant.

Before this recognition, QSevidence had passed the MedClaw special evaluation for medical and health intelligent assistants under the China Academy of Information and Communications Technology intelligent-agent evaluation system, becoming the first medical and health intelligent assistant in China to pass that special evaluation. In March 2026, QSevidence MedClaw Skills Store was officially launched. Around clinical diagnosis and treatment, public health, medical imaging, laboratory medicine, hospital management, nursing management, medical record management and medication management, it has formed more than 2,000 specialized skills, further improving adaptation and efficiency across medical and health scenarios.

The two honors, 2026 AIGC company to watch and 2026 AIGC product to watch, reflect industry recognition of Qingsong Health's medical AI innovation and scenario implementation. Looking ahead, Qingsong Health will continue to use technology to empower health services, deepen the integration of AI with the medical and health industry, and bring trustworthy, usable and implementable medical AI capabilities into more real-world scenarios.

Original source: https://www.qingsonghealth.com/show-94.html